JOSEPH KHOURY to Molecular Targeted Therapy
This is a "connection" page, showing publications JOSEPH KHOURY has written about Molecular Targeted Therapy.
Connection Strength
0.505
-
Next-generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med. 2015 Jan; 139(1):11-3.
Score: 0.234
-
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Curr Hematol Malig Rep. 2020 08; 15(4):372-381.
Score: 0.086
-
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.
Score: 0.079
-
The evolving potential of companion diagnostics. Scand J Clin Lab Invest Suppl. 2016; 245:S22-5.
Score: 0.065
-
Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J. 2021 05 20; 11(5):98.
Score: 0.023
-
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am J Hematol. 2018 03; 93(3):371-374.
Score: 0.018